Besides, Combined inhibition of both MEK and CDK4/6 is effective in preclinical models of KRAS mutant CRC (Colorectal Cancer) and justifies a planned phase II clinical trial in patients with refractory KRAS-mutant CRC27. Here, CDK4 is linked to colorectal carcinoma.